2. UroToday Home
  3. Video Lectures

Advanced Bladder Cancer Videos

Overall Response Rate After Immune-Checkpoint Inhibitor Initiation and Post-ICI PFS in Patients With Advanced Urothelial Carcinoma - Dimitrios Makrakis
May 24, 2022
Details
Outcomes Between Patients With and Without Prior Intravesical BCG, Who Received Immune Checkpoint Inhibitors for Advanced Urothelial Carcinoma - Rafee Talukder & Petros Grivas
May 11, 2022
Details
Antibody-Drug Conjugates in Advanced Urothelial Cancer: Clinical Perspective - Scott Tagawa
April 14, 2022
Details
Final Analysis of the ATLANTIS Rucaparib Arm - Simon Crabb
May 13, 2022
Details
Practice Changing Publications in Urothelial Carcinoma - Deborah Kaye
April 3, 2022
Details
Treatment Strategies in Advanced Urothelial Carcinoma - Stephen Boorjian
March 29, 2022
Details
The Future of Adjuvant and Neoadjuvant Therapy for Patients with Muscle-Invasive Bladder Cancer - Tracy Rose
March 21, 2022
Details
Clinical Outcomes With Anti-PD(L)1 Immune Checkpoint Inhibitors in Patients With Advanced Urothelial Carcinoma – Dimitrios Makrakis
February 1, 2022
Details
Bladder Cancer Advocacy Network's (BCAN) Young Investigator Award Program - Elizabeth Plimack
January 28, 2022
Details
Biomarkers and Next Generation Sequencing in Advanced Bladder Cancer - Noah Hahn
December 16, 2021
Details
Cisplatin-Related Immunomodulation and Efficacy with Atezolizumab + Cisplatin Versus Carboplatin-Based Chemotherapy in Metastatic Urothelial Cancer - Matthew Galsky
November 4, 2021
Details
Implications for Genetic Testing in Urothelial Cancer - Guru Sonpavde & Maria Carlo
August 17, 2021
Details
Sacituzumab Govitecan in Patients With Metastatic Urothelial Carcinoma, Progressing After Platinum-Based Chemotherapy and Checkpoint Inhibitors: TROPHY-U-01 Journal Club – Christopher Wallis & Zachary Klaassen
July 30, 2021
Details
Neoadjuvant Atezolizumab with Gemcitabine and Cisplatin in Patients with Muscle-Invasive Bladder Cancer - Samuel A. Funt
July 29, 2021
Details
Durability and Long Term Outcome of Enfortumab Vedotin + Pembrolizumab in the EV-103 Study in Cisplatin-Ineligible Locally Advanced or Metastatic Urothelial Carcinoma – Terence W. Friedlander
July 29, 2021
Details
Updated Results from EV-201 Cohort 2 - Enfortumab Vedotin Is A Potential Non-Platinum Option for Cisplatin-Ineligible Patients Following Anti-PD-1/L1 Treatment - Bradley McGregor
June 10, 2021
Details
Advances in the Treatment of Metastatic Urothelial Cancer - Matthew Galsky
May 24, 2021
Details
Intersection of Biology and Clinical Characteristics Towards Personalized Sequential Treatments for MIBC - Andrea Necchi and Ewan Gibb
May 14, 2021
Details
TROPHY-U-01 Results Lead to Accelerated Approval of Sacituzumab Govitecan (Trodelvy) for Pretreated Metastatic Urothelial Carcinoma - Scott Tagawa
May 1, 2021
Details
Practical Considerations for Administering Avelumab Maintenance in Clinical Practice - Petros Grivas and Neeraj Agarwal
April 23, 2021
Details
Voluntary Withdrawal In The US of Durvalumab and of Atezolizumab in Metastatic Urothelial Carcinoma - Petros Grivas
April 22, 2021
Details
Characterization of The Genomic Landscape of Post-Neoadjuvant Chemotherapy in MIBC Patients- Andrew Lenis
January 24, 2021
Details
Metastatic and Muscle-Invasive Bladder Cancer European Association of Urology (EAU) Guidelines - J. Alfred Witjes
December 8, 2020
Details
Molecular Changes Associated with Treatment Response in Muscle-Invasive Bladder Cancer Patients Treated with Cisplatin-Based Chemotherapy - Lars Dyrskjøt
November 12, 2020
Details
Two-year JAVELIN Solid Tumor Data Phase 1 Final Results - Andrea Apolo
November 17, 2020
Details
Comparing Nab-Paclitaxel and Paclitaxel in Platinum-Refractory Bladder Cancer - Srikala Sridhar
November 4, 2020
Details
Implications for Reducing Disparities in Muscle-Invasive Bladder Cancer - Samuel Washington III
November 1, 2020
Details
Guidelines for Advanced Urothelial Carcinoma in First-line Treatment for Patients Ineligible or Unfit for Cisplatin - Michiel S. Van der Heijden
November 1, 2020
Details
Evaluating Treatments in Advanced Urothelial Carcinoma - Guru Sonpavde
October 21, 2020
Details
Association Between Clinical Outcomes and Exploratory Biomarkers in the JAVELIN Bladder 100 Trial, Advanced Urothelial Carcinoma - Srikala Sridhar
October 14, 2020
Details
ESMO 2020: The TROPHY-U-01 Study- Sacituzumab Govitecan for Advanced Urothelial Carcinoma - Petros Grivas
September 29, 2020
Details
ESMO 2020: Combination Therapies in Locally Advanced or Metastatic Urothelial Carcinoma Bladder Cancer - Josh Meeks
September 28, 2020
Details
Current Treatment Approaches in Advanced Urothelial Carcinoma - Shilpa Gupta
September 8, 2020
Details
The Dynamic Advancements in Personalized Treatments for Metastatic Urothelial Cancer - Andrea Apolo
August 24, 2020
Details
Prolonging Overall Survival in Patients with Muscle-Invasive Bladder Cancer - Petros Grivas
July 30, 2020
Details
Treatment Approach: Case Study in Aggressiveness Metastatic Urothelial Carcinoma - Makarand Khochikar
August 10, 2020
Details
Advancements in Treatments for Metastatic Urothelial Carcinoma (mUC) - Petros Grivas
June 29, 2020
Details
JAVELIN Bladder 100: Results of First-line Maintenance Therapy Plus Best Supportive Care Demonstrates Significant Prolonged OS in Advanced Urothelial Cancer - Cora Sternberg
June 28, 2020
Details
Assessing the Potential Cost-Effectiveness of the Addition of Atezolizumab to First-Line Platinum Chemotherapy in Advanced Urothelial Carcinoma - Ali Khaki
June 11, 2020
Details
Progress in Bladder Cancer Research - Bishoy Faltas
June 3, 2020
Details
IMvigor010 Primary Analysis from a Phase III Randomized Study of Adjuvant Atezolizumab versus Observation in High-Risk Muscle-Invasive Urothelial Carcinoma - Thomas Powles & Matthew Galsky
May 31, 2020
Details
JAVELIN Bladder 100: Avelumab for Previously Untreated Locally Advanced or Metastatic Urothelial Carcinoma - Thomas Powles
May 31, 2020
Details
Controversial and Complex Cases in Urothelial Cancer - Srikala Sridhar
May 2, 2020
Details
The Impact of Molecular Subtyping and Immune Infiltration on Pathological Response and Outcome Following Neoadjuvant Pembrolizumab in MIBC - Andrea Necchi
April 28, 2020
Details
The Landscape of Advanced Bladder Cancer: A Review of the Last 30-Years - Cora Sternberg
March 23, 2020
Details
Enfortumab Vedotin for Advanced Urothelial Carcinoma - Jonathan Rosenberg
March 8, 2020
Details
Updates on Bladder Cancer Clinical Trials ASCO GU 2020 - Matthew Galsky
February 26, 2020
Details
Recent Advances in the Treatment of Metastatic Urothelial Cancer - Petros Grivas
February 22, 2020
Details
Treatments in Development for Muscle-invasive Bladder Cancer - Min Yuen Teo
January 15, 2020
Details
Advanced Bladder Cancer Clinic: Are you Ready? - Neal Shore
December 18, 2019
Details
Immunotherapy and Chemotherapy Use in Patients with Metastatic Bladder Cancer - Ronac Mamtani and Ravi Parikh
November 25, 2019
Details
Circulating Tumor DNA in Urothelial Cancer - Interview with Bishoy Faltas
October 16, 2019
Details
Upper Tract Urothelial Carcinoma Has a Luminal-Papillary T-cell Depleted Contexture and Activated FGFR3 Signaling - Bishoy Faltas
October 14, 2019
Details
Fibroblast Growth Factor Receptor 3 Alterations and Response to PD-1/PD-L1 Blockade in Patients with Metastatic Urothelial Cancer - Matt Galsky
September 17, 2019
Details
Antibody Drug Conjugates for the Treatment of Metastatic Urothelial Carcinoma - Petros Grivas
July 8, 2019
Details
Erdafitinib Treatment in Metastatic Urothelial Carcinoma - Petros Grivas
July 25, 2019
Details
Biomarker Testing in Metastatic Urothelial Carcinoma - Petros Grivas
August 5, 2019
Details
The Performance Status and Response to Immune Checkpoint Inhibition in Patients with Advanced Urothelial Carcinoma - Ali Khaki
December 13, 2019
Details
Results from CALGB 90601 in Metastatic Urothelial Carcinoma - Jonathan Rosenberg
July 2, 2019
Details
Novel New Approaches in the Neoadjuvant Disease Setting for Bladder Cancer - Petros Grivas
June 24, 2019
Details
Urinary Diversion after Radical Cystectomy - Morgan Roupret
June 17, 2019
Details
Assessing and Managing Toxicities with Immune Checkpoint Inhibitors - Brenda Martone
June 13, 2019
Details
Erdafitinib in Bladder Cancer - Arjun Balar
May 20, 2019
Details
Implications of Clinical Response Following Neoadjuvant Chemotherapy - Seth Lerner
April 19, 2019
Details
Treating Advanced Bladder Cancer - Petros Grivas
July 5, 2019
Details
Optimizing Treatment Outcomes in Muscle Invasive Bladder Cancer (MIBC) - Wassim Kassouf
July 23, 2019
Details
Bladder Sparing Strategies for Urothelial Cancer - Jason Efstathiou
June 21, 2019
Details
Neoadjuvant Treatment in Muscle Invasive Bladder Cancer- Andrea Necchi
June 3, 2019
Details
Antibody-drug Conjugate (ADC) Sacituzumab Govitecan in Metastatic UroThelial Carcinoma - Scott Tagawa
March 26, 2019
Details
Joshua J. Meeks on SWOG 1806 Study
April 1, 2019
Details
Combination Approaches with Immune-Checkpoint Blockade in Bladder Cancer - Matthew Galsky
February 28, 2019
Details
Immune Checkpoint Inhibitors Trials in Urothelial Cancer: Recent Updates and Future Outlook - Andrea Apolo
February 23, 2019
Details
A Conversation on Immuno-Oncology in Bladder Cancer - Petros Grivas
November 14, 2018
Details
Update on Immunotherapy Advances in Renal and Bladder Cancer - Cora Sternberg
October 29, 2018
Details
Advances in Bladder Cancer Beyond Immunotherapy and Checkpoint Inhibitors - Evan Yu
October 8, 2018
Details
Atezolizumab in Metastatic Urothelial Carcinoma Outside Clinical Trials -Pedro Barata
August 29, 2018
Details
Updates on Health-Related Quality-of-Life (HRQoL) analyses in GU Oncology - Cora Sternberg
July 24, 2018
Details
The State of Advanced Bladder Cancer - New Data from AACR 2018 - Interview with Arjun Balar
May 4, 2018
Details
email news signup